Absolutely remarkable: striking effects of infusion time-of-day on immunochemotherapy efficacy in nonsmall cell lung cancer in a randomized phase 3 trial www.nature.com/articles/s41...
Roychoudhuri Lab
In this randomized phase 3 trial, patients with treatment-naive stage III–IV nonsmall cell lung cancer who received sintilimab or pembrolizumab in combination with chemotherapy early in the day (befor...
